Permanente physician leader Stephen Parodi, MD, was among the experts discussing how technology helps drive preventive care and healing as care extends into the home.
On the front lines of Kaiser Permanente’s pandemic response, infectious disease leaders play a key role in sharing research, building guidelines, and charting a national roadmap to flatten the coronavirus curve.
This year’s flu season arrives with the backdrop of a pandemic, prompting physicians and health officials to get creative in promoting flu shots and finding safe ways to deliver the vaccine, according to a recently published Washington Post story.
Citing record numbers of COVID-19 cases in California’s hospital system – including 800 patients hospitalized at Kaiser Permanente medical centers in California – Stephen Parodi, MD, told CNN International that it’s time to reinstate some of the coronavirus safety measures that had been lifted in recent weeks.
Stephen Parodi, MD, executive vice president of The Permanente Federation and national infectious disease leader at Kaiser Permanente, recently discussed the effects of disparate approaches to COVID-19 interventions across the United States with The Wall Street Journal.
Stephen Parodi, MD, national infectious disease leader for Kaiser Permanente, commented in Fierce Healthcare on Kaiser Permanente’s multipronged COVID-19 suppression strategy, which was outlined in a NEJM Catalyst article earlier this week. That strategy includes 8 key capabilities health systems need to consider as the country reopens.
In an article published this week in NEJM Catalyst, Kaiser Permanente physicians and leaders acknowledge the conundrum of reopening the country for business while preventing successive waves of coronavirus infection, and describe the next strategic phase in the battle against the COVID-19 pandemic: disease suppression.
Stephen Parodi, MD, an associate executive director of The Permanente Medical Group in Northern California, told Voice of America that Kaiser Permanente is working with “light speed” to build a new 7,000-square-foot testing lab in Berkeley.
Stephen Parodi, MD, associate executive director of The Permanente Medical Group and national infectious disease leader for Kaiser Permanente, spoke with CBSN recently about why trials with remdesivir and other drugs matter. CBSN is the CBS News 24/7 digital streaming service.
To provide the best experience, we use cookies to store and/or access device information, and to process data such as browsing behavior or unique IDs. Please click Accept to give us permission to personalize content and enable analytics. Note that opting out may adversely affect your access to certain features and functions, such as video and audio playback.
Functional
Always active
These cookies are essential for the site to function. The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.These cookies allow us to gather nonidentifiable information such as number of site visits. The technical storage or access is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
These cookies can be used to provide you with relevant advertisements, although we do not typically target users with ads. The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.